Stem cell therapy for fertility at Femcare Fertility, Kalyani Nagar, Pune is offered for selected cases of thin endometrium and premature ovarian insufficiency. Dr. Sayali Chavan Shitole provides evidence-based guidance on candidacy, realistic outcomes and the current state of clinical evidence. Consultation: ₹500.
Stem cell therapy in reproductive medicine is one of the most discussed and least clearly explained areas in modern fertility care. Patients researching IVF failures or difficult diagnoses encounter the term frequently - but the information available ranges from genuinely promising research to clinics making claims that far outstrip the current evidence.
At Femcare Fertility in Kalyani Nagar, Pune, Dr. Sayali Chavan Shitole offers a clear, honest explanation of what stem cell and regenerative approaches currently offer, which patients are candidates and what realistic outcomes look like. No promises are made that the science does not support.
Endometrial regeneration - rebuilding a thin or scarred uterine lining that does not respond adequately to oestrogen
Ovarian rejuvenation - attempting to restore some function in ovaries with severely diminished reserve or premature ovarian insufficiency (POI)
A thin endometrial lining - generally less than 7mm at the time of embryo transfer - is one of the most frustrating obstacles in IVF. Standard oestrogen treatment works for most patients, but a subset of women, particularly those with Asherman's syndrome, previous uterine infections, or extensive curettage, do not respond.
Approaches currently under clinical investigation include:Platelet-Rich Plasma (PRP) infusion - growth factors derived from the patient's own blood are infused into the uterine cavity. Several small studies show improvement in endometrial thickness and IVF outcomes, though large randomised trials are still ongoing
Bone marrow-derived stem cell infusion - a research-stage approach showing early promise in severely scarred endometria
Dr. Sayali discusses these options with patients who have repeatedly thin endometrium despite standard treatment, clearly explaining the level of evidence behind each approach.
POI - ovarian failure before age 40 - is a devastating diagnosis for women hoping to conceive with their own eggs. Conventional fertility medicine has limited options when ovaries are no longer producing eggs. Research into ovarian rejuvenation using platelet-rich plasma (PRP) injected directly into the ovary has shown early promise in a small number of published studies - some women have had detectable follicle activity resume after the procedure.
It is important to be clear: ovarian PRP is still an investigational treatment. The evidence base is growing but not yet at the level required to make it a standard recommendation. Dr. Sayali discusses it as an option for women with POI who have exhausted standard treatments and wish to explore every possibility before considering donor eggs.
Women with documented thin endometrium ("<"7mm) that has not responded to standard oestrogen therapy over multiple cycles
Women with a history of Asherman's syndrome who have had hysteroscopic adhesiolysis but endometrial recovery is incomplete
Women with premature ovarian insufficiency who have no detectable follicles on standard ultrasound, considered after thorough counselling on evidence and realistic chances
Dr. Sayali recommends that any patient considering stem cell or regenerative therapy for fertility ask the following:
What is the published evidence for this treatment - is it from case reports, small series, or randomised controlled trials?
How many patients have been treated at this clinic with this approach?
What are the realistic outcomes and what is the next step if it does not work?
At Femcare Fertility, all three questions receive honest, complete answers.